董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| John R. Stuelpnagel | 男 | Chairman of the Board, Director | 68 | 28.34万美元 | 249.13 | 2026-01-01 |
| Sridhar Kosaraju | 男 | Director | 48 | 22.33万美元 | 未持股 | 2026-01-01 |
| Shehnaaz Suliman | 女 | Director | 55 | 21.10万美元 | 14.46 | 2026-01-01 |
| Serge Saxonov | -- | Chief Executive Officer and Director | 49 | 632.92万美元 | 494.73 | 2026-01-01 |
| Benjamin J. Hindson | 男 | Chief Scientific Officer, President and Director | 51 | 260.48万美元 | 341.46 | 2026-01-01 |
| Alan Mateo | 男 | Director | 63 | 20.83万美元 | 6.80 | 2026-01-01 |
| Sarah Teichmann | 女 | Director | 49 | 19.83万美元 | 1.73 | 2026-01-01 |
| Kimberly J. Popovits | 女 | Director | 67 | 21.63万美元 | 5.49 | 2026-01-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Serge Saxonov | -- | Chief Executive Officer and Director | 49 | 632.92万美元 | 494.73 | 2026-01-01 |
| Benjamin J. Hindson | 男 | Chief Scientific Officer, President and Director | 51 | 260.48万美元 | 341.46 | 2026-01-01 |
| Adam S. Taich | 男 | Chief Financial Officer | 50 | 223.31万美元 | 10.57 | 2026-01-01 |
| Randy Wu | -- | General Counsel and Secretary | -- | 未披露 | 未持股 | 2026-01-01 |
董事简历
中英对照 | 中文 | 英文- John R. Stuelpnagel
-
John R. Stuelpnagel，自2013年8月起担任董事会主席。此外，Stuelpnagel博士在2009年10月至2015年1月Ariosa Diagnostics被出售给罗氏时共同创立并担任执行董事长。他还是Sequenta在2010年11月至2015年1月期间的董事长，当时该公司与Adaptive生物技术合并，他在2015年1月至2017年11月继续担任该公司的董事会成员。Stuelpnagel博士自2009年8月起担任Fabric Genomics董事长，自2017年4月起担任Inscripta董事长，自2017年5月起担任Encoded Therapeutics董事会成员。此前，Stuelpnagel博士于1998年与他人共同创立了依诺米那，并曾在该公司工作至2009年3月。在加入依诺米那之前，Stuelpnagel博士于1997年至1998年担任CW集团的合伙人。Stuelpnagel博士在加州大学戴维斯分校获得生物化学学士学位和兽医博士学位，在加州大学洛杉矶分校获得工商管理硕士学位。
John R. Stuelpnagel,has been Chairman of board of directors since August 2013. In addition, Dr. Stuelpnagel co-founded and was Executive Chairman of Ariosa Diagnostics from October 2009 to January 2015 when that company was sold to Roche. He was also the Chairman of Sequenta from November 2010 to January 2015 when that company was merged with Adaptive Biotechnologies where he continued as a member of their board of directors from January 2015 to November 2017. Dr. Stuelpnagel has served as the Chairman of Fabric Genomics since August 2009, the Chairman of Inscripta since April 2017 and a member of the board of directors for Encoded Therapeutics since May 2017. Previously, Dr. Stuelpnagel co-founded Illumina in 1998 where he worked until March 2009. Prior to Illumina, Dr. Stuelpnagel was an associate at CW Group from 1997 to 1998. Dr. Stuelpnagel received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles. - John R. Stuelpnagel，自2013年8月起担任董事会主席。此外，Stuelpnagel博士在2009年10月至2015年1月Ariosa Diagnostics被出售给罗氏时共同创立并担任执行董事长。他还是Sequenta在2010年11月至2015年1月期间的董事长，当时该公司与Adaptive生物技术合并，他在2015年1月至2017年11月继续担任该公司的董事会成员。Stuelpnagel博士自2009年8月起担任Fabric Genomics董事长，自2017年4月起担任Inscripta董事长，自2017年5月起担任Encoded Therapeutics董事会成员。此前，Stuelpnagel博士于1998年与他人共同创立了依诺米那，并曾在该公司工作至2009年3月。在加入依诺米那之前，Stuelpnagel博士于1997年至1998年担任CW集团的合伙人。Stuelpnagel博士在加州大学戴维斯分校获得生物化学学士学位和兽医博士学位，在加州大学洛杉矶分校获得工商管理硕士学位。
- John R. Stuelpnagel,has been Chairman of board of directors since August 2013. In addition, Dr. Stuelpnagel co-founded and was Executive Chairman of Ariosa Diagnostics from October 2009 to January 2015 when that company was sold to Roche. He was also the Chairman of Sequenta from November 2010 to January 2015 when that company was merged with Adaptive Biotechnologies where he continued as a member of their board of directors from January 2015 to November 2017. Dr. Stuelpnagel has served as the Chairman of Fabric Genomics since August 2009, the Chairman of Inscripta since April 2017 and a member of the board of directors for Encoded Therapeutics since May 2017. Previously, Dr. Stuelpnagel co-founded Illumina in 1998 where he worked until March 2009. Prior to Illumina, Dr. Stuelpnagel was an associate at CW Group from 1997 to 1998. Dr. Stuelpnagel received his B.S. in Biochemistry and his Doctorate in Veterinary Medicine from the University of California, Davis and his M.B.A. from the University of California, Los Angeles.
- Sridhar Kosaraju
-
Sridhar Kosaraju，自2019年4月起担任董事会成员。Kosaraju先生自2020年10月起担任Inscripta总裁兼首席执行官。此外，Kosaraju先生自2021年8月起担任医疗器械上市公司Nevro Corp.的董事会成员。此前，Kosaraju先生曾于2019年8月至2020年5月担任医疗器械上市公司Penumbra的总裁，于2015年5月至2019年11月担任首席财务官，并于2015年5月至2019年8月担任战略主管。在加入Penumbra之前，他于1999年至2015年5月在J.P. Morgan Securities LLC从事投资银行工作，曾担任多个职位，先后承担更大责任，最近担任股票资本市场董事总经理、医疗保健股票资本市场主管以及技术、媒体、电信股票资本市场联席主管。在2006年进入摩根大通股票资本市场集团之前，Kosaraju先生曾在摩根大通的多个业务集团任职，包括2003年至2006年的股票衍生品以及1999年至2003年的技术、媒体、电信投资银行业务。他于1999年获得麻省理工学院的学士学位。
Sridhar Kosaraju,has served on board of directors since April 2019. Mr. Kosaraju has served as President and Chief Executive Officer of Inscripta since October 2020. In addition, Mr. Kosaraju has served on the board of Nevro Corp., a publicly traded medical device company, since August 2021. Previously, Mr. Kosaraju served as President of Penumbra, a publicly traded medical device company, from August 2019 to May 2020, Chief Financial Officer from May 2015 to November 2019 and as Head of Strategy from May 2015 to August 2019. Prior to joining Penumbra, he worked in investment banking for J.P. Morgan Securities LLC from 1999 to May 2015, where he held a variety of positions with successively greater responsibility, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Prior to entering J.P. Morgan's equity capital markets group in 2006, Mr. Kosaraju served in various practice groups at J.P. Morgan, including Equity Derivatives from 2003 to 2006 and Technology, Media, Telecom Investment Banking Coverage from 1999 to 2003. He received a B.S. from Massachusetts Institute of Technology in 1999. - Sridhar Kosaraju，自2019年4月起担任董事会成员。Kosaraju先生自2020年10月起担任Inscripta总裁兼首席执行官。此外，Kosaraju先生自2021年8月起担任医疗器械上市公司Nevro Corp.的董事会成员。此前，Kosaraju先生曾于2019年8月至2020年5月担任医疗器械上市公司Penumbra的总裁，于2015年5月至2019年11月担任首席财务官，并于2015年5月至2019年8月担任战略主管。在加入Penumbra之前，他于1999年至2015年5月在J.P. Morgan Securities LLC从事投资银行工作，曾担任多个职位，先后承担更大责任，最近担任股票资本市场董事总经理、医疗保健股票资本市场主管以及技术、媒体、电信股票资本市场联席主管。在2006年进入摩根大通股票资本市场集团之前，Kosaraju先生曾在摩根大通的多个业务集团任职，包括2003年至2006年的股票衍生品以及1999年至2003年的技术、媒体、电信投资银行业务。他于1999年获得麻省理工学院的学士学位。
- Sridhar Kosaraju,has served on board of directors since April 2019. Mr. Kosaraju has served as President and Chief Executive Officer of Inscripta since October 2020. In addition, Mr. Kosaraju has served on the board of Nevro Corp., a publicly traded medical device company, since August 2021. Previously, Mr. Kosaraju served as President of Penumbra, a publicly traded medical device company, from August 2019 to May 2020, Chief Financial Officer from May 2015 to November 2019 and as Head of Strategy from May 2015 to August 2019. Prior to joining Penumbra, he worked in investment banking for J.P. Morgan Securities LLC from 1999 to May 2015, where he held a variety of positions with successively greater responsibility, most recently Managing Director of Equity Capital Markets, Head of Healthcare Equity Capital Markets and co-Head of Technology, Media, Telecom Equity Capital Markets. Prior to entering J.P. Morgan's equity capital markets group in 2006, Mr. Kosaraju served in various practice groups at J.P. Morgan, including Equity Derivatives from 2003 to 2006 and Technology, Media, Telecom Investment Banking Coverage from 1999 to 2003. He received a B.S. from Massachusetts Institute of Technology in 1999.
- Shehnaaz Suliman
-
Shehnaaz Suliman，自2019年8月起担任董事会或董事。她自2022年1月起担任民营基因药物公司ReCode Therapeutics的首席执行官和董事会成员。此外，苏利曼博士自2019年1月起担任上市生物制药公司Ultragenyx Pharmaceutical Inc.的董事会成员。此前，她于2019年12月至2022年1月担任Alector，Inc.总裁兼首席运营官，于2020年1月至2022年1月担任Alector，Inc.临时首席商务官。苏里曼博士于2017年7月至2019年3月担任Theravance Biopharma公司企业发展和战略高级副总裁。在担任Theravance职务之前，Suliman博士曾任职于罗氏和基因泰克，于2010年9月至2015年5月在基因泰克担任研发组合管理和运营组的组长和项目组组长，随后于2015年6月至2017年7月担任罗氏合作伙伴副总裁兼全球治疗领域负责人。在加入基因泰克公司之前，Suliman博士曾于2005年1月至2010年9月期间在吉利德科学公司担任过各种管理职务，责任越来越大。在加入吉利德之前，苏利曼博士是雷曼兄弟和Petkevich & Partners的投资银行家。此前，她曾于2017年10月至2019年7月担任私营生物制药公司Parvus Therapeutics，Inc.的董事会成员。苏利曼博士在南非开普敦大学医学院获得医学博士学位（MB，ChB），并拥有卓越的工商管理硕士学位，以及牛津大学发展研究硕士学位，她曾是该大学的罗德学者。
Shehnaaz Suliman,has served on board or directors since August 2019. She has served as Chief Executive Officer and a member of the board of directors of ReCode Therapeutics, a privately-held genetic medicines company since January 2022. In addition, Dr. Suliman has served on the board of directors for Ultragenyx Pharmaceutical Inc., a publicly-traded biopharmaceutical company since January 2019. Previously, she served as President and Chief Operating Officer of Alector, Inc. from December 2019 to January 2022 and as interim Chief Business Officer of Alector, Inc. from January 2020 to January 2022. Dr. Suliman served as Senior Vice President, Corporate Development and Strategy of Theravance Biopharma, Inc, from July 2017 to March 2019. Prior to her position at Theravance, Dr. Suliman worked for Roche and Genentech, Inc., as Group Leader and Project Team Leader in the R&D Portfolio Management and Operations Group at Genentech from September 2010 to May 2015 and then as Vice President and Global Therapeutic Area Head, Roche Partnering from June 2015 to July 2017. Prior to Genentech, Dr. Suliman held various management roles of increasing responsibility at Gilead Sciences, Inc., between January 2005 and September 2010. Prior to Gilead, Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners. She previously served as a member of the board of directors of Parvus Therapeutics, Inc., a privately-held biopharmaceutical company from October 2017 to July 2019. Dr. Suliman received her M.D. (MB, ChB) at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes Scholar. - Shehnaaz Suliman，自2019年8月起担任董事会或董事。她自2022年1月起担任民营基因药物公司ReCode Therapeutics的首席执行官和董事会成员。此外，苏利曼博士自2019年1月起担任上市生物制药公司Ultragenyx Pharmaceutical Inc.的董事会成员。此前，她于2019年12月至2022年1月担任Alector，Inc.总裁兼首席运营官，于2020年1月至2022年1月担任Alector，Inc.临时首席商务官。苏里曼博士于2017年7月至2019年3月担任Theravance Biopharma公司企业发展和战略高级副总裁。在担任Theravance职务之前，Suliman博士曾任职于罗氏和基因泰克，于2010年9月至2015年5月在基因泰克担任研发组合管理和运营组的组长和项目组组长，随后于2015年6月至2017年7月担任罗氏合作伙伴副总裁兼全球治疗领域负责人。在加入基因泰克公司之前，Suliman博士曾于2005年1月至2010年9月期间在吉利德科学公司担任过各种管理职务，责任越来越大。在加入吉利德之前，苏利曼博士是雷曼兄弟和Petkevich & Partners的投资银行家。此前，她曾于2017年10月至2019年7月担任私营生物制药公司Parvus Therapeutics，Inc.的董事会成员。苏利曼博士在南非开普敦大学医学院获得医学博士学位（MB，ChB），并拥有卓越的工商管理硕士学位，以及牛津大学发展研究硕士学位，她曾是该大学的罗德学者。
- Shehnaaz Suliman,has served on board or directors since August 2019. She has served as Chief Executive Officer and a member of the board of directors of ReCode Therapeutics, a privately-held genetic medicines company since January 2022. In addition, Dr. Suliman has served on the board of directors for Ultragenyx Pharmaceutical Inc., a publicly-traded biopharmaceutical company since January 2019. Previously, she served as President and Chief Operating Officer of Alector, Inc. from December 2019 to January 2022 and as interim Chief Business Officer of Alector, Inc. from January 2020 to January 2022. Dr. Suliman served as Senior Vice President, Corporate Development and Strategy of Theravance Biopharma, Inc, from July 2017 to March 2019. Prior to her position at Theravance, Dr. Suliman worked for Roche and Genentech, Inc., as Group Leader and Project Team Leader in the R&D Portfolio Management and Operations Group at Genentech from September 2010 to May 2015 and then as Vice President and Global Therapeutic Area Head, Roche Partnering from June 2015 to July 2017. Prior to Genentech, Dr. Suliman held various management roles of increasing responsibility at Gilead Sciences, Inc., between January 2005 and September 2010. Prior to Gilead, Dr. Suliman was an investment banker with Lehman Brothers and Petkevich & Partners. She previously served as a member of the board of directors of Parvus Therapeutics, Inc., a privately-held biopharmaceutical company from October 2017 to July 2019. Dr. Suliman received her M.D. (MB, ChB) at the University of Cape Town Medical School, South Africa, and holds an M.B.A, with distinction, and M.Phil. in Development Studies degrees from Oxford University, where she was a Rhodes Scholar.
- Serge Saxonov
-
Serge Saxonov共同创立了10X Genomics，并自2012年7月起担任我们的首席执行官和董事会成员。从2012年7月到2012年10月，Saxonov博士还担任我们的总裁。在共同创立我们公司之前，2010年5月至2012年4月，Saxonov博士是Quantalife（一家私营生命科学公司，开发并商业化了液滴数字聚合酶链反应平台）应用程序的Vice President。Saxonov博士从2006年6月到2010年5月担任23Andme（一家私人持有的个人基因组学和生物技术公司）研究与开发的创始架构师和董事。Saxonov博士在斯坦福大学（Stanford University）获得生物医学信息学博士学位，在哈佛学院（Harvard College）获得应用数学学士学位。
Serge Saxonov,co-founded 10x Genomics, Inc. and has served as Chief Executive Officer and on board of directors since July 2012. Dr. Saxonov also served as President from July 2012 until October 2012. Prior to co-founding company, Dr. Saxonov was Vice President of Applications at QuantaLife, a privately-held life sciences company, from May 2010 to April 2012. Dr. Saxonov served as Founding Architect and Director of research and development at 23andMe, a personal genomics and biotechnology company, from June 2006 until May 2010. Dr. Saxonov received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College. - Serge Saxonov共同创立了10X Genomics，并自2012年7月起担任我们的首席执行官和董事会成员。从2012年7月到2012年10月，Saxonov博士还担任我们的总裁。在共同创立我们公司之前，2010年5月至2012年4月，Saxonov博士是Quantalife（一家私营生命科学公司，开发并商业化了液滴数字聚合酶链反应平台）应用程序的Vice President。Saxonov博士从2006年6月到2010年5月担任23Andme（一家私人持有的个人基因组学和生物技术公司）研究与开发的创始架构师和董事。Saxonov博士在斯坦福大学（Stanford University）获得生物医学信息学博士学位，在哈佛学院（Harvard College）获得应用数学学士学位。
- Serge Saxonov,co-founded 10x Genomics, Inc. and has served as Chief Executive Officer and on board of directors since July 2012. Dr. Saxonov also served as President from July 2012 until October 2012. Prior to co-founding company, Dr. Saxonov was Vice President of Applications at QuantaLife, a privately-held life sciences company, from May 2010 to April 2012. Dr. Saxonov served as Founding Architect and Director of research and development at 23andMe, a personal genomics and biotechnology company, from June 2006 until May 2010. Dr. Saxonov received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.
- Benjamin J. Hindson
-
BenjaminJ.Hindson于2012年7月共同创立了10X Genomics，自2012年10月以来一直担任我们的首席科学官兼总裁，并自2012年7月以来一直担任我们的董事会成员。Hindson博士从2012年7月到2012年10月担任我司技术总裁兼财务主管，从2012年10月到2014年4月担任秘书。在共同创立我们公司之前，Hindson博士从2008年8月开始担任Quantalife的联合创始人兼首席科学官，直到2011年10月该公司被出售给Bio-Rad Laboratories。Hindson从2002年到2008年担任Lawrence Livermore National Laboratory化学和生物武器不扩散项目多个职位。Hindson博士获得了理学学士学位。以及他在澳大利亚迪肯大学（Deakin University）获得的化学博士学位。
Benjamin J. Hindson,co-founded 10x Genomics, Inc. in July 2012, has served as Chief Scientific Officer and President since October 2012 and has served on board of directors since July 2012. Dr. Hindson served as President of Technology and Treasurer from July 2012 until October 2012 and as Secretary from October 2012 until April 2014. Prior to co-founding company, Dr. Hindson was Co-founder and Chief Scientific Officer of QuantaLife, a privately-held life sciences company from August 2008 until its sale to Bio-Rad Laboratories in October 2011. From 2002 to 2008, Dr. Hindson served in various positions at Lawrence Livermore National Laboratory in the Chemical and Biological Weapons Non-proliferation Program. Dr. Hindson earned his B.Sc. in Chemistry and his Ph.D. in Chemistry from Deakin University, Australia. - BenjaminJ.Hindson于2012年7月共同创立了10X Genomics，自2012年10月以来一直担任我们的首席科学官兼总裁，并自2012年7月以来一直担任我们的董事会成员。Hindson博士从2012年7月到2012年10月担任我司技术总裁兼财务主管，从2012年10月到2014年4月担任秘书。在共同创立我们公司之前，Hindson博士从2008年8月开始担任Quantalife的联合创始人兼首席科学官，直到2011年10月该公司被出售给Bio-Rad Laboratories。Hindson从2002年到2008年担任Lawrence Livermore National Laboratory化学和生物武器不扩散项目多个职位。Hindson博士获得了理学学士学位。以及他在澳大利亚迪肯大学（Deakin University）获得的化学博士学位。
- Benjamin J. Hindson,co-founded 10x Genomics, Inc. in July 2012, has served as Chief Scientific Officer and President since October 2012 and has served on board of directors since July 2012. Dr. Hindson served as President of Technology and Treasurer from July 2012 until October 2012 and as Secretary from October 2012 until April 2014. Prior to co-founding company, Dr. Hindson was Co-founder and Chief Scientific Officer of QuantaLife, a privately-held life sciences company from August 2008 until its sale to Bio-Rad Laboratories in October 2011. From 2002 to 2008, Dr. Hindson served in various positions at Lawrence Livermore National Laboratory in the Chemical and Biological Weapons Non-proliferation Program. Dr. Hindson earned his B.Sc. in Chemistry and his Ph.D. in Chemistry from Deakin University, Australia.
- Alan Mateo
-
Alan Mateo，自2024年6月起担任董事会或董事。他目前担任Veeva Systems Inc.的顾问，此前曾于2015年4月至2024年4月期间担任该公司全球销售执行副总裁。在加入Veeva之前，Mateo先生曾于2005年3月至2015年2月在生命科学基于云的解决方案平台提供商Medidata Solutions, Inc.担任多个主管职务，包括于2014年1月至2015年2月担任现场运营执行副总裁。在加入Medidata之前，Mateo先生在PeopleSoft工作了九年，负责产品线销售、销售运营以及将京东 Edwards整合到PeopleSoft的全球销售组织中。在加入仁科科技之前，Mateo先生是供应链管理规划应用软件提供商Red Pepper Software Co.的东北销售总监，以及京东 Edwards的大客户主管。Mateo先生在Juniata学院获得了计算机科学和市场营销的理学学士学位。
Alan Mateo,has served on board or directors since June 2024. He currently serves as an advisor to Veeva Systems Inc., where he previously served as Executive Vice President, Global Sales from April 2015 to April 2024. Prior to joining Veeva, Mr. Mateo served in various executive roles at Medidata Solutions, Inc., a provider of a platform of cloud-based solutions for life sciences, from March 2005 to February 2015, including as Executive Vice President of Field Operations from January 2014 to February 2015. Before Medidata, Mr. Mateo spent nine years at PeopleSoft, where his responsibilities included product lines sales, sales operations and the integration of JD Edwards into PeopleSoft's global sales organization. Prior to PeopleSoft, Mr. Mateo was Northeast Sales Director for Red Pepper Software Co., a provider of supply chain management planning application software, and a major account executive at JD Edwards. Mr. Mateo earned a Bachelor of Science in both Computer Science and Marketing from Juniata College. - Alan Mateo，自2024年6月起担任董事会或董事。他目前担任Veeva Systems Inc.的顾问，此前曾于2015年4月至2024年4月期间担任该公司全球销售执行副总裁。在加入Veeva之前，Mateo先生曾于2005年3月至2015年2月在生命科学基于云的解决方案平台提供商Medidata Solutions, Inc.担任多个主管职务，包括于2014年1月至2015年2月担任现场运营执行副总裁。在加入Medidata之前，Mateo先生在PeopleSoft工作了九年，负责产品线销售、销售运营以及将京东 Edwards整合到PeopleSoft的全球销售组织中。在加入仁科科技之前，Mateo先生是供应链管理规划应用软件提供商Red Pepper Software Co.的东北销售总监，以及京东 Edwards的大客户主管。Mateo先生在Juniata学院获得了计算机科学和市场营销的理学学士学位。
- Alan Mateo,has served on board or directors since June 2024. He currently serves as an advisor to Veeva Systems Inc., where he previously served as Executive Vice President, Global Sales from April 2015 to April 2024. Prior to joining Veeva, Mr. Mateo served in various executive roles at Medidata Solutions, Inc., a provider of a platform of cloud-based solutions for life sciences, from March 2005 to February 2015, including as Executive Vice President of Field Operations from January 2014 to February 2015. Before Medidata, Mr. Mateo spent nine years at PeopleSoft, where his responsibilities included product lines sales, sales operations and the integration of JD Edwards into PeopleSoft's global sales organization. Prior to PeopleSoft, Mr. Mateo was Northeast Sales Director for Red Pepper Software Co., a provider of supply chain management planning application software, and a major account executive at JD Edwards. Mr. Mateo earned a Bachelor of Science in both Computer Science and Marketing from Juniata College.
- Sarah Teichmann
-
Sarah Teichmann，自2024年7月起担任董事会或董事。她自2024年4月起担任剑桥大学干细胞研究所和医学系干细胞医学教授，自2016年10月起担任剑桥大学丘吉尔学院高级研究员，此前曾于1999年至2015年担任剑桥大学三一学院初级研究员、后任教学研究员和研究主任，并于2013年至2024年4月担任剑桥大学卡文迪什实验室（物理系）研究主任。Teichmann博士自2016年10月与他人共同创立了描述人体内所有细胞类型的一项倡议HCA以来，一直担任人类细胞图谱（HCA）组委会的联合主席，并自2020年4月起担任Human Cell Atlas，Inc.的董事会联合主席，该组织是一家支持HCA的非营利性501（c）（3）组织。此外，Teichmann博士自2024年1月起担任跨国制药公司Glaxo Smith Kline plc的转化研究、呼吸与免疫学副总裁，并自2023年9月起担任EnsoCell Therapeutics的联合创始人、顾问、首席科学官和董事会成员，EnsoCell Therapeutics是一家私营药物发现公司，负责空间基因组学、人工智能和机器学习方法。2016年2月至2023年12月，她在威康桑格研究所担任细胞遗传学负责人，并于2013年2月至2024年4月担任高级组长，并于2016年2月至2023年12月担任执行董事会成员。2013年2月至2016年1月，她在欧洲分子生物学实验室（EMBL）欧洲生物信息学研究所担任研究组组长。2001年10月至2013年1月，她在剑桥的医学研究理事会（MRC）分子生物学实验室担任项目负责人。Teichmann博士在2000年1月至2001年9月期间担任伦敦大学学院的拜特纪念研究员。她是欧洲分子生物学组织（EMBO）成员，也是医学科学院和皇家学会的院士，也是国际计算生物学学会的院士。Teichmann博士在剑桥大学获得计算基因组学博士学位，以及自然科学（生物化学）学士和硕士学位。
Sarah Teichmann,has served on board or directors since July 2024. She has served as the Chair in Stem Cell Medicine at the University of Cambridge's Stem Cell Institute and Department of Medicine since April 2024 and as Senior Research Fellow at the University of Cambridge's Churchill College since October 2016, having previously served as Junior Research Fellow and then Teaching Fellow and Director of Studies at the University of Cambridge's Trinity College from 1999 to 2015 and Director of Research in the University of Cambridge's Cavendish Laboratory (Physics Department) from 2013 to April 2024. Dr. Teichmann has served as co-chair of the Human Cell Atlas (HCA) Organizing Committee since co- founding the HCA, an initiative to describe all cell types in the human body, in October 2016 and has served as co-chair of the board of directors of Human Cell Atlas, Inc., a nonprofit 501(c)(3) organization which supports the HCA, since April 2020. Additionally, Dr. Teichmann has served as Vice President, Translational Research, Respiratory & Immunology at Glaxo Smith Kline plc, a multinational pharmaceutical company, since January 2024, and as a co-founder, consultant, Chief Scientific Officer and board member of EnsoCell Therapeutics, a private drug discovery company 10x Genomics, Inc. ing spatial genomics, artificial intelligence and machine learning methods, since September 2023. From February 2016 to December 2023, she served as Head of Cellular Genetics at the Wellcome Sanger Institute, where she also served as Senior Group Leader from February 2013 to April 2024 and as a member of the executive board from February 2016 to December 2023. From February 2013 to January 2016, she served as Research Group Leader at the European Molecular Biology Laboratory's (EMBL) European Bioinformatics Institute. From October 2001 to January 2013, she served as Programme Leader at the Medical Research Council's (MRC) Laboratory of Molecular Biology in Cambridge. Dr. Teichmann was a Beit Memorial Fellow at University College London from January 2000 to September 2001. She is a European Molecular Biology Organization (EMBO) member and a Fellow of the Academy of Medical Sciences and Royal Society, as well as a Fellow of the International Society of Computational Biology. Dr. Teichmann received a Ph.D. in Computational Genomics, as well as a B.A. and M.A. in Natural Sciences (Biochemistry), from the University of Cambridge. - Sarah Teichmann，自2024年7月起担任董事会或董事。她自2024年4月起担任剑桥大学干细胞研究所和医学系干细胞医学教授，自2016年10月起担任剑桥大学丘吉尔学院高级研究员，此前曾于1999年至2015年担任剑桥大学三一学院初级研究员、后任教学研究员和研究主任，并于2013年至2024年4月担任剑桥大学卡文迪什实验室（物理系）研究主任。Teichmann博士自2016年10月与他人共同创立了描述人体内所有细胞类型的一项倡议HCA以来，一直担任人类细胞图谱（HCA）组委会的联合主席，并自2020年4月起担任Human Cell Atlas，Inc.的董事会联合主席，该组织是一家支持HCA的非营利性501（c）（3）组织。此外，Teichmann博士自2024年1月起担任跨国制药公司Glaxo Smith Kline plc的转化研究、呼吸与免疫学副总裁，并自2023年9月起担任EnsoCell Therapeutics的联合创始人、顾问、首席科学官和董事会成员，EnsoCell Therapeutics是一家私营药物发现公司，负责空间基因组学、人工智能和机器学习方法。2016年2月至2023年12月，她在威康桑格研究所担任细胞遗传学负责人，并于2013年2月至2024年4月担任高级组长，并于2016年2月至2023年12月担任执行董事会成员。2013年2月至2016年1月，她在欧洲分子生物学实验室（EMBL）欧洲生物信息学研究所担任研究组组长。2001年10月至2013年1月，她在剑桥的医学研究理事会（MRC）分子生物学实验室担任项目负责人。Teichmann博士在2000年1月至2001年9月期间担任伦敦大学学院的拜特纪念研究员。她是欧洲分子生物学组织（EMBO）成员，也是医学科学院和皇家学会的院士，也是国际计算生物学学会的院士。Teichmann博士在剑桥大学获得计算基因组学博士学位，以及自然科学（生物化学）学士和硕士学位。
- Sarah Teichmann,has served on board or directors since July 2024. She has served as the Chair in Stem Cell Medicine at the University of Cambridge's Stem Cell Institute and Department of Medicine since April 2024 and as Senior Research Fellow at the University of Cambridge's Churchill College since October 2016, having previously served as Junior Research Fellow and then Teaching Fellow and Director of Studies at the University of Cambridge's Trinity College from 1999 to 2015 and Director of Research in the University of Cambridge's Cavendish Laboratory (Physics Department) from 2013 to April 2024. Dr. Teichmann has served as co-chair of the Human Cell Atlas (HCA) Organizing Committee since co- founding the HCA, an initiative to describe all cell types in the human body, in October 2016 and has served as co-chair of the board of directors of Human Cell Atlas, Inc., a nonprofit 501(c)(3) organization which supports the HCA, since April 2020. Additionally, Dr. Teichmann has served as Vice President, Translational Research, Respiratory & Immunology at Glaxo Smith Kline plc, a multinational pharmaceutical company, since January 2024, and as a co-founder, consultant, Chief Scientific Officer and board member of EnsoCell Therapeutics, a private drug discovery company 10x Genomics, Inc. ing spatial genomics, artificial intelligence and machine learning methods, since September 2023. From February 2016 to December 2023, she served as Head of Cellular Genetics at the Wellcome Sanger Institute, where she also served as Senior Group Leader from February 2013 to April 2024 and as a member of the executive board from February 2016 to December 2023. From February 2013 to January 2016, she served as Research Group Leader at the European Molecular Biology Laboratory's (EMBL) European Bioinformatics Institute. From October 2001 to January 2013, she served as Programme Leader at the Medical Research Council's (MRC) Laboratory of Molecular Biology in Cambridge. Dr. Teichmann was a Beit Memorial Fellow at University College London from January 2000 to September 2001. She is a European Molecular Biology Organization (EMBO) member and a Fellow of the Academy of Medical Sciences and Royal Society, as well as a Fellow of the International Society of Computational Biology. Dr. Teichmann received a Ph.D. in Computational Genomics, as well as a B.A. and M.A. in Natural Sciences (Biochemistry), from the University of Cambridge.
- Kimberly J. Popovits
-
Kimberly J. Popovits， 自2009年1月起担任总裁和首席执行官；自2012年3月1日起担任董事长。之前她从2002年2月到2009年1月担任总裁和首席运营官。从1987年11月到2002年2月在Genentech有限公司（一家生物制药公司）担任多个职位，包括最近的职位从2001年2月到2002年2月担任市场和销售高级副总裁；1994年10月到2001年2月担任销售副总裁。加入Genentech之前，她曾担任American Critical Care（医院医疗保健产品供应商）东南地区分部经理。此外，她从2005年7月开始担任 Nuvelo有限公司董事，直到2009年1月Nuvelo被ARCA biopharma有限公司收购。她持有密歇根州立大学商业学士学位。
Kimberly J. Popovits,has served as a member of Board of Directors since February 2018. Ms. Popovits served as Genomic Health's Chairman of the Board from 2012 through 2019, and Chief Executive Officer and President from 2009 through 2019. She was President and Chief Operating Officer upon joining the company in 2002. Prior to leading Genomic Health, Ms. Popovits served as Senior Vice President, Marketing and Sales at Genentech, Inc. ("Genentech"). During her 15 years at Genentech, Ms. Popovits led the successful commercialization of 14 new therapies, including Herceptin. Ms. Popovits currently serves on the board of directors of 10x Genomics, Inc., Exact Sciences Corp., Kardigan, Talis Biomedical Corporation, Wamberg Genomic Advisors, and Genomic Life, Inc. and previously served on the board of directors of MyoKardia, Inc. She also serves as an Executive Advisor to Blackstone Life Sciences and is an Advisor to the Healthcare Businesswomen's Association. Ms. Popovits holds a B.A. in Business from Michigan State University. - Kimberly J. Popovits， 自2009年1月起担任总裁和首席执行官；自2012年3月1日起担任董事长。之前她从2002年2月到2009年1月担任总裁和首席运营官。从1987年11月到2002年2月在Genentech有限公司（一家生物制药公司）担任多个职位，包括最近的职位从2001年2月到2002年2月担任市场和销售高级副总裁；1994年10月到2001年2月担任销售副总裁。加入Genentech之前，她曾担任American Critical Care（医院医疗保健产品供应商）东南地区分部经理。此外，她从2005年7月开始担任 Nuvelo有限公司董事，直到2009年1月Nuvelo被ARCA biopharma有限公司收购。她持有密歇根州立大学商业学士学位。
- Kimberly J. Popovits,has served as a member of Board of Directors since February 2018. Ms. Popovits served as Genomic Health's Chairman of the Board from 2012 through 2019, and Chief Executive Officer and President from 2009 through 2019. She was President and Chief Operating Officer upon joining the company in 2002. Prior to leading Genomic Health, Ms. Popovits served as Senior Vice President, Marketing and Sales at Genentech, Inc. ("Genentech"). During her 15 years at Genentech, Ms. Popovits led the successful commercialization of 14 new therapies, including Herceptin. Ms. Popovits currently serves on the board of directors of 10x Genomics, Inc., Exact Sciences Corp., Kardigan, Talis Biomedical Corporation, Wamberg Genomic Advisors, and Genomic Life, Inc. and previously served on the board of directors of MyoKardia, Inc. She also serves as an Executive Advisor to Blackstone Life Sciences and is an Advisor to the Healthcare Businesswomen's Association. Ms. Popovits holds a B.A. in Business from Michigan State University.
高管简历
中英对照 | 中文 | 英文- Serge Saxonov
Serge Saxonov共同创立了10X Genomics，并自2012年7月起担任我们的首席执行官和董事会成员。从2012年7月到2012年10月，Saxonov博士还担任我们的总裁。在共同创立我们公司之前，2010年5月至2012年4月，Saxonov博士是Quantalife（一家私营生命科学公司，开发并商业化了液滴数字聚合酶链反应平台）应用程序的Vice President。Saxonov博士从2006年6月到2010年5月担任23Andme（一家私人持有的个人基因组学和生物技术公司）研究与开发的创始架构师和董事。Saxonov博士在斯坦福大学（Stanford University）获得生物医学信息学博士学位，在哈佛学院（Harvard College）获得应用数学学士学位。
Serge Saxonov,co-founded 10x Genomics, Inc. and has served as Chief Executive Officer and on board of directors since July 2012. Dr. Saxonov also served as President from July 2012 until October 2012. Prior to co-founding company, Dr. Saxonov was Vice President of Applications at QuantaLife, a privately-held life sciences company, from May 2010 to April 2012. Dr. Saxonov served as Founding Architect and Director of research and development at 23andMe, a personal genomics and biotechnology company, from June 2006 until May 2010. Dr. Saxonov received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.- Serge Saxonov共同创立了10X Genomics，并自2012年7月起担任我们的首席执行官和董事会成员。从2012年7月到2012年10月，Saxonov博士还担任我们的总裁。在共同创立我们公司之前，2010年5月至2012年4月，Saxonov博士是Quantalife（一家私营生命科学公司，开发并商业化了液滴数字聚合酶链反应平台）应用程序的Vice President。Saxonov博士从2006年6月到2010年5月担任23Andme（一家私人持有的个人基因组学和生物技术公司）研究与开发的创始架构师和董事。Saxonov博士在斯坦福大学（Stanford University）获得生物医学信息学博士学位，在哈佛学院（Harvard College）获得应用数学学士学位。
- Serge Saxonov,co-founded 10x Genomics, Inc. and has served as Chief Executive Officer and on board of directors since July 2012. Dr. Saxonov also served as President from July 2012 until October 2012. Prior to co-founding company, Dr. Saxonov was Vice President of Applications at QuantaLife, a privately-held life sciences company, from May 2010 to April 2012. Dr. Saxonov served as Founding Architect and Director of research and development at 23andMe, a personal genomics and biotechnology company, from June 2006 until May 2010. Dr. Saxonov received a Ph.D. in biomedical informatics from Stanford University and an A.B. in applied mathematics from Harvard College.
- Benjamin J. Hindson
BenjaminJ.Hindson于2012年7月共同创立了10X Genomics，自2012年10月以来一直担任我们的首席科学官兼总裁，并自2012年7月以来一直担任我们的董事会成员。Hindson博士从2012年7月到2012年10月担任我司技术总裁兼财务主管，从2012年10月到2014年4月担任秘书。在共同创立我们公司之前，Hindson博士从2008年8月开始担任Quantalife的联合创始人兼首席科学官，直到2011年10月该公司被出售给Bio-Rad Laboratories。Hindson从2002年到2008年担任Lawrence Livermore National Laboratory化学和生物武器不扩散项目多个职位。Hindson博士获得了理学学士学位。以及他在澳大利亚迪肯大学（Deakin University）获得的化学博士学位。
Benjamin J. Hindson,co-founded 10x Genomics, Inc. in July 2012, has served as Chief Scientific Officer and President since October 2012 and has served on board of directors since July 2012. Dr. Hindson served as President of Technology and Treasurer from July 2012 until October 2012 and as Secretary from October 2012 until April 2014. Prior to co-founding company, Dr. Hindson was Co-founder and Chief Scientific Officer of QuantaLife, a privately-held life sciences company from August 2008 until its sale to Bio-Rad Laboratories in October 2011. From 2002 to 2008, Dr. Hindson served in various positions at Lawrence Livermore National Laboratory in the Chemical and Biological Weapons Non-proliferation Program. Dr. Hindson earned his B.Sc. in Chemistry and his Ph.D. in Chemistry from Deakin University, Australia.- BenjaminJ.Hindson于2012年7月共同创立了10X Genomics，自2012年10月以来一直担任我们的首席科学官兼总裁，并自2012年7月以来一直担任我们的董事会成员。Hindson博士从2012年7月到2012年10月担任我司技术总裁兼财务主管，从2012年10月到2014年4月担任秘书。在共同创立我们公司之前，Hindson博士从2008年8月开始担任Quantalife的联合创始人兼首席科学官，直到2011年10月该公司被出售给Bio-Rad Laboratories。Hindson从2002年到2008年担任Lawrence Livermore National Laboratory化学和生物武器不扩散项目多个职位。Hindson博士获得了理学学士学位。以及他在澳大利亚迪肯大学（Deakin University）获得的化学博士学位。
- Benjamin J. Hindson,co-founded 10x Genomics, Inc. in July 2012, has served as Chief Scientific Officer and President since October 2012 and has served on board of directors since July 2012. Dr. Hindson served as President of Technology and Treasurer from July 2012 until October 2012 and as Secretary from October 2012 until April 2014. Prior to co-founding company, Dr. Hindson was Co-founder and Chief Scientific Officer of QuantaLife, a privately-held life sciences company from August 2008 until its sale to Bio-Rad Laboratories in October 2011. From 2002 to 2008, Dr. Hindson served in various positions at Lawrence Livermore National Laboratory in the Chemical and Biological Weapons Non-proliferation Program. Dr. Hindson earned his B.Sc. in Chemistry and his Ph.D. in Chemistry from Deakin University, Australia.
- Adam S. Taich
Adam S. Taich，自2024年8月起担任首席财务官。Taich先生此前曾于2024年1月至2024年7月担任Standard BioTools公司首席战略官。此前，他曾于2023年3月在蛋白质组学公司SomaLogic公司担任临时首席执行官，直至2024年1月SomaLogic被TERM1收购。Taich先生于2021年11月至2023年3月担任SomaLogic的首席商务官，并于2022年4月至2023年3月担任SomaLogic的生命科学执行副总裁。在加入SomaLogic之前，Taich先生在科学仪器、试剂和软件服务的全球供应商ThermoFisher Scientific工作了19年，担任过多个职务，包括2020年2月至2021年6月担任副总裁兼总经理—分子生物学，2018年4月至2020年2月担任副总裁—战略和业务发展，2016年10月至2018年4月担任副总裁&；总经理—蛋白质和细胞分析，2013年11月至2016年10月担任副总裁兼总经理—全球服务和支持，并于2004年至2013年担任其他多个职务。Taich先生拥有俄亥俄州牛津迈阿密大学政治学和俄语学士学位。
Adam S. Taich,has served as Chief Financial Officer since August 2024. Mr. Taich previously served as Chief Strategy Officer of Standard BioTools Inc. from January 2024 to July 2024. He previously served as interim Chief Executive Officer of SomaLogic, Inc., a proteomics company, from March 2023 until SomaLogic's acquisition by Standard BioTools in January 2024. Mr. Taich served as SomaLogic's Chief Business Officer from November 2021 to March 2023 as well as SomaLogic's Executive Vice President of Life Sciences from April 2022 to March 2023. Prior to joining SomaLogic, Mr. Taich spent 19 years at ThermoFisher Scientific, a global supplier of scientific instrumentation, reagents and software services, in various roles including as Vice President & General Manager-Molecular Biology from February 2020 to June 2021, Vice President—Strategy and Business Development from April 2018 to February 2020, Vice President & General Manager— Protein and Cell Analysis from October 2016 to April 2018, Vice President & General Manager—Global Services and Support from November 2013 to October 2016 and in various other roles from 2004 to 2013. Mr. Taich holds a B.A. in Political Science and Russian from Miami University in Oxford, Ohio.- Adam S. Taich，自2024年8月起担任首席财务官。Taich先生此前曾于2024年1月至2024年7月担任Standard BioTools公司首席战略官。此前，他曾于2023年3月在蛋白质组学公司SomaLogic公司担任临时首席执行官，直至2024年1月SomaLogic被TERM1收购。Taich先生于2021年11月至2023年3月担任SomaLogic的首席商务官，并于2022年4月至2023年3月担任SomaLogic的生命科学执行副总裁。在加入SomaLogic之前，Taich先生在科学仪器、试剂和软件服务的全球供应商ThermoFisher Scientific工作了19年，担任过多个职务，包括2020年2月至2021年6月担任副总裁兼总经理—分子生物学，2018年4月至2020年2月担任副总裁—战略和业务发展，2016年10月至2018年4月担任副总裁&；总经理—蛋白质和细胞分析，2013年11月至2016年10月担任副总裁兼总经理—全球服务和支持，并于2004年至2013年担任其他多个职务。Taich先生拥有俄亥俄州牛津迈阿密大学政治学和俄语学士学位。
- Adam S. Taich,has served as Chief Financial Officer since August 2024. Mr. Taich previously served as Chief Strategy Officer of Standard BioTools Inc. from January 2024 to July 2024. He previously served as interim Chief Executive Officer of SomaLogic, Inc., a proteomics company, from March 2023 until SomaLogic's acquisition by Standard BioTools in January 2024. Mr. Taich served as SomaLogic's Chief Business Officer from November 2021 to March 2023 as well as SomaLogic's Executive Vice President of Life Sciences from April 2022 to March 2023. Prior to joining SomaLogic, Mr. Taich spent 19 years at ThermoFisher Scientific, a global supplier of scientific instrumentation, reagents and software services, in various roles including as Vice President & General Manager-Molecular Biology from February 2020 to June 2021, Vice President—Strategy and Business Development from April 2018 to February 2020, Vice President & General Manager— Protein and Cell Analysis from October 2016 to April 2018, Vice President & General Manager—Global Services and Support from November 2013 to October 2016 and in various other roles from 2004 to 2013. Mr. Taich holds a B.A. in Political Science and Russian from Miami University in Oxford, Ohio.
- Randy Wu
Randy Wu,2016年8月加入公司，此前曾在Orrick，Herrington & Sutcliffe LLP担任律师。吴博士拥有美国加州大学旧金山分校生物物理学博士学位、斯坦福大学法学院法学博士学位和哈佛大学化学硕士学位。
Randy Wu,joined the Company in August 2016 after working as an attorney at Orrick, Herrington & Sutcliffe LLP. Dr. Wu holds a Ph.D. in Biophysics from the University of California, San Francisco, a J.D. from Stanford Law School and an A.B. in Chemistry from Harvard University.- Randy Wu,2016年8月加入公司，此前曾在Orrick，Herrington & Sutcliffe LLP担任律师。吴博士拥有美国加州大学旧金山分校生物物理学博士学位、斯坦福大学法学院法学博士学位和哈佛大学化学硕士学位。
- Randy Wu,joined the Company in August 2016 after working as an attorney at Orrick, Herrington & Sutcliffe LLP. Dr. Wu holds a Ph.D. in Biophysics from the University of California, San Francisco, a J.D. from Stanford Law School and an A.B. in Chemistry from Harvard University.